Does the media refer more to XENE or MRNA?

In the previous week, Moderna had 19 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 25 mentions for Moderna and 6 mentions for Xenon Pharmaceuticals. Moderna's average media sentiment score of 0.49 beat Xenon Pharmaceuticals' score of 0.42 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 12 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 4 Very Negative mention(s) Neutral

Does the media favor VTRS or XENE?

In the previous week, Xenon Pharmaceuticals had 2 more articles in the media than Viatris. MarketBeat recorded 6 mentions for Xenon Pharmaceuticals and 4 mentions for Viatris. Viatris' average media sentiment score of 0.77 beat Xenon Pharmaceuticals' score of 0.42 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer XENE or GMAB?

In the previous week, Xenon Pharmaceuticals had 3 more articles in the media than Genmab A/S. MarketBeat recorded 6 mentions for Xenon Pharmaceuticals and 3 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.10 beat Xenon Pharmaceuticals' score of 0.42 indicating that Genmab A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genmab A/S 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer XENE or BBIO?

In the previous week, BridgeBio Pharma had 6 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 12 mentions for BridgeBio Pharma and 6 mentions for Xenon Pharmaceuticals. BridgeBio Pharma's average media sentiment score of 0.75 beat Xenon Pharmaceuticals' score of 0.42 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer XENE or ASND?

In the previous week, Ascendis Pharma A/S had 5 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 11 mentions for Ascendis Pharma A/S and 6 mentions for Xenon Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 1.28 beat Xenon Pharmaceuticals' score of 0.42 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ascendis Pharma A/S 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Xenon Pharmaceuticals (XENE) Competitors

$52.79 +1.58 (+3.09%)

Closing price 06/9/2026 04:00 PM Eastern

Extended Trading

$52.78 -0.01 (-0.01%)

As of 06/9/2026 04:10 PM Eastern

Compare

XENE vs. MRNA, VTRS, GMAB, BBIO, and ASND

Should you buy Xenon Pharmaceuticals stock or one of its competitors? MarketBeat compares Xenon Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Xenon Pharmaceuticals include Moderna (MRNA), Viatris (VTRS), Genmab A/S (GMAB), BridgeBio Pharma (BBIO), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.

How does Xenon Pharmaceuticals compare to Moderna?

Xenon Pharmaceuticals (NASDAQ:XENE) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Xenon Pharmaceuticals has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
Moderna	-143.55%	-26.64%	-19.32%

Xenon Pharmaceuticals has higher earnings, but lower revenue than Moderna. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	680.43	-$345.91M	-$4.70	N/A
Moderna	$1.94B	9.74	-$2.82B	-$8.15	N/A

Xenon Pharmaceuticals has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

Xenon Pharmaceuticals currently has a consensus target price of $77.20, suggesting a potential upside of 46.24%. Moderna has a consensus target price of $36.60, suggesting a potential downside of 23.32%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Xenon Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

In the previous week, Moderna had 19 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 25 mentions for Moderna and 6 mentions for Xenon Pharmaceuticals. Moderna's average media sentiment score of 0.49 beat Xenon Pharmaceuticals' score of 0.42 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	12 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	4 Very Negative mention(s)	Neutral

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 4.1% of Xenon Pharmaceuticals shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Xenon Pharmaceuticals beats Moderna on 9 of the 17 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to Viatris?

Viatris (NASDAQ:VTRS) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Xenon Pharmaceuticals has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

Viatris has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

Viatris currently has a consensus price target of $17.50, indicating a potential upside of 8.02%. Xenon Pharmaceuticals has a consensus price target of $77.20, indicating a potential upside of 46.24%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Xenon Pharmaceuticals has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.32	-$3.51B	-$0.26	N/A
Xenon Pharmaceuticals	$7.50M	680.43	-$345.91M	-$4.70	N/A

In the previous week, Xenon Pharmaceuticals had 2 more articles in the media than Viatris. MarketBeat recorded 6 mentions for Xenon Pharmaceuticals and 4 mentions for Viatris. Viatris' average media sentiment score of 0.77 beat Xenon Pharmaceuticals' score of 0.42 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.9% of Viatris shares are owned by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Comparatively, 4.1% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Xenon Pharmaceuticals beats Viatris on 11 of the 17 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to Genmab A/S?

Xenon Pharmaceuticals (NASDAQ:XENE) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

Xenon Pharmaceuticals currently has a consensus price target of $77.20, indicating a potential upside of 46.24%. Genmab A/S has a consensus price target of $37.93, indicating a potential upside of 51.11%. Given Genmab A/S's higher probable upside, analysts plainly believe Genmab A/S is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Xenon Pharmaceuticals has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

Genmab A/S has a net margin of 21.05% compared to Xenon Pharmaceuticals' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
Genmab A/S	21.05%	15.34%	8.94%

Genmab A/S has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	680.43	-$345.91M	-$4.70	N/A
Genmab A/S	$3.72B	4.21	$963M	$1.32	19.02

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 4.1% of Xenon Pharmaceuticals shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Xenon Pharmaceuticals had 3 more articles in the media than Genmab A/S. MarketBeat recorded 6 mentions for Xenon Pharmaceuticals and 3 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.10 beat Xenon Pharmaceuticals' score of 0.42 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genmab A/S	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Genmab A/S beats Xenon Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to BridgeBio Pharma?

Xenon Pharmaceuticals (NASDAQ:XENE) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Xenon Pharmaceuticals has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

Xenon Pharmaceuticals presently has a consensus target price of $77.20, indicating a potential upside of 46.24%. BridgeBio Pharma has a consensus target price of $89.59, indicating a potential upside of 32.37%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Xenon Pharmaceuticals is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.85

Xenon Pharmaceuticals has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	680.43	-$345.91M	-$4.70	N/A
BridgeBio Pharma	$502.08M	26.40	-$724.93M	-$3.74	N/A

In the previous week, BridgeBio Pharma had 6 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 12 mentions for BridgeBio Pharma and 6 mentions for Xenon Pharmaceuticals. BridgeBio Pharma's average media sentiment score of 0.75 beat Xenon Pharmaceuticals' score of 0.42 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Pharma	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 4.1% of Xenon Pharmaceuticals shares are owned by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Xenon Pharmaceuticals has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Summary

BridgeBio Pharma beats Xenon Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Xenon Pharmaceuticals compare to Ascendis Pharma A/S?

Xenon Pharmaceuticals (NASDAQ:XENE) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 4.1% of Xenon Pharmaceuticals shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Ascendis Pharma A/S had 5 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 11 mentions for Ascendis Pharma A/S and 6 mentions for Xenon Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 1.28 beat Xenon Pharmaceuticals' score of 0.42 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	680.43	-$345.91M	-$4.70	N/A
Ascendis Pharma A/S	$814.57M	16.33	-$258M	$8.67	24.59

Xenon Pharmaceuticals currently has a consensus price target of $77.20, indicating a potential upside of 46.24%. Ascendis Pharma A/S has a consensus price target of $295.39, indicating a potential upside of 38.53%. Given Xenon Pharmaceuticals' higher possible upside, equities research analysts clearly believe Xenon Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

Ascendis Pharma A/S has a net margin of 57.87% compared to Xenon Pharmaceuticals' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Xenon Pharmaceuticals has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

Summary

Ascendis Pharma A/S beats Xenon Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Get Xenon Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XENE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XENE vs. The Competition

Export

Metric	Xenon Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.95B	$3.30B	$6.65B	$12.06B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-11.23	18.68	24.74	23.76
Price / Sales	680.43	297.55	508.64	105.22
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	7.01	8.06	10.47	6.72
Net Income	-$345.91M	$23.83M	$3.56B	$337.35M
7 Day Performance	-1.25%	-2.51%	-0.96%	-1.21%
1 Month Performance	-6.47%	2.22%	1.25%	1.41%
1 Year Performance	64.15%	36.40%	20.49%	23.64%

Xenon Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XENE Xenon Pharmaceuticals	3.5046 of 5 stars	$52.79 +3.1%	$77.20 +46.2%	+67.9%	$4.95B	$7.50M	N/A	210
MRNA Moderna	1.3723 of 5 stars	$47.60 +0.3%	$36.60 -23.1%	+69.6%	$18.82B	$1.94B	N/A	4,700	Trending News Analyst Forecast Insider Trade
VTRS Viatris	2.9424 of 5 stars	$15.93 +0.3%	$17.50 +9.9%	+83.9%	$18.49B	$14.30B	N/A	30,000	Positive News
GMAB Genmab A/S	4.4759 of 5 stars	$24.80 -1.4%	$37.93 +52.9%	+12.8%	$15.68B	$3.72B	18.79	3,029
BBIO BridgeBio Pharma	3.5629 of 5 stars	$67.37 -0.4%	$89.59 +33.0%	+73.4%	$13.24B	$502.08M	N/A	400	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XENE) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xenon Pharmaceuticals (XENE) Competitors

XENE vs. MRNA, VTRS, GMAB, BBIO, and ASND

How does Xenon Pharmaceuticals compare to Moderna?

Summary

How does Xenon Pharmaceuticals compare to Viatris?

Summary

How does Xenon Pharmaceuticals compare to Genmab A/S?

Summary

How does Xenon Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does Xenon Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XENE vs. The Competition

Xenon Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xenon Pharmaceuticals (XENE) Competitors

XENE vs. MRNA, VTRS, GMAB, BBIO, and ASND

How does Xenon Pharmaceuticals compare to Moderna?

Is XENE or MRNA more profitable?

Which has better valuation and earnings, XENE or MRNA?

Which has more volatility & risk, XENE or MRNA?

Do analysts prefer XENE or MRNA?

Does the media refer more to XENE or MRNA?

Do institutionals & insiders have more ownership in XENE or MRNA?

Summary

How does Xenon Pharmaceuticals compare to Viatris?

Is VTRS or XENE more profitable?

Which has more volatility and risk, VTRS or XENE?

Do analysts prefer VTRS or XENE?

Which has stronger valuation and earnings, VTRS or XENE?

Does the media favor VTRS or XENE?

Do institutionals and insiders have more ownership in VTRS or XENE?

Summary

How does Xenon Pharmaceuticals compare to Genmab A/S?

Do analysts recommend XENE or GMAB?

Which has more risk and volatility, XENE or GMAB?

Is XENE or GMAB more profitable?

Which has stronger earnings and valuation, XENE or GMAB?

Do institutionals & insiders believe in XENE or GMAB?

Does the media prefer XENE or GMAB?

Summary

How does Xenon Pharmaceuticals compare to BridgeBio Pharma?

Which has more risk and volatility, XENE or BBIO?

Do analysts prefer XENE or BBIO?

Which has better valuation & earnings, XENE or BBIO?

Does the media prefer XENE or BBIO?

Do institutionals and insiders believe in XENE or BBIO?

Is XENE or BBIO more profitable?

Summary

How does Xenon Pharmaceuticals compare to Ascendis Pharma A/S?

Do insiders and institutionals believe in XENE or ASND?

Does the media prefer XENE or ASND?

Which has higher earnings and valuation, XENE or ASND?

Do analysts rate XENE or ASND?

Is XENE or ASND more profitable?

Which has more volatility and risk, XENE or ASND?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XENE vs. The Competition

Xenon Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools